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Abstract 
Background 
Despite hepatitis B vaccination at birth and at 6, 10 and 14 weeks of age, hepatitis B virus 
(HBV) infection continues to be endemic in the Lao People’s Democratic Republic (PDR). 
We carried out a cross-sectional serological study in infants, pre-school children, school 
pupils and pregnant women to determine their burden of disease, risk of infection and 
vaccination status. 
Methods 
A total of 2471 participants between 9 months and 46 years old were recruited from urban 
(Vientiane Capital, Luang Prabang), semi-urban (Boulhikhamxai and Savannakhet) and 
remote rural areas (Huaphan). All sera were tested for anti-HBs and anti-HBc. Sera testing 
positive for anti-HBc alone were further tested for the presence of HBsAg. 
Results 
A low prevalence of HBsAg (0.5%) was detected among infants from Vientiane and Luang 
Prabang, indicating some success of the vaccination policy. However, only 65.6% had 
protective anti-HBs antibodies, suggesting that vaccination coverage or responses remain 
sub-optimal, even in these urban populations. 
In pre-school children from remote areas in Huaphan, 21.2% were positive for anti-HBc 
antibodies, and 4.6% were for HBsAg positive, showing that a significant proportion of 
children in these rural regions have early exposure to HBV. In pre-school children with 3 
documented HBV vaccinations, only 17.0% (15/55) were serologically protected. 
Among school-children from semi-urban regions of Luang Prabang, Boulhikhamxai and 
Savannakhet provinces, those below the age of 9 who were born after HBV vaccine 
introduction had anti-HBc and HBsAg prevalence of 11.7% and 4.1%, respectively. The 
prevalence increased to 19.4% and 7.8% of 10–14 year olds and to 27% and 10.2% of 15–19 
year olds. 
Pregnant women from Luang Prabang and Vientiane had very high anti-HBc and HBsAg 
prevalence (49.5% and 8.2%), indicating high exposure and risk of onward vertical 
transmission to the unborn infant. 
Conclusions 
Overall, the results demonstrate a dramatic deficiency in vaccination coverage and vaccine 
responses and/or documentation within the regions of Lao PDR studied, which included 
urbanized areas with better health care access. Timely and effective hepatitis B vaccination 
coverage is needed in Lao PDR. 
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Background 
Hepatitis B virus (HBV) infects more than one third of the world’s population and there are 
an estimated 360 million chronic carriers worldwide, with a high risk for cirrhosis, 
hepatocellular carcinomas and liver failure [1,2]. Half of the global HBV-attributable deaths 
occur in the WHO Western Pacific Region which includes the Lao People’s Democratic 
Republic (PDR) [3]. The prevalence of HBV infection is extremely heterogeneous between 
and within countries in the WPR. The WHO regional committee has recommended a target to 
reduce the prevalence of chronic hepatitis B infections among children aged younger than 5 
years to less than 1% by 2017 [4-6]. 
HBV is endemic in the Lao PDR, about 8% of blood donors being chronic carriers of HBV, 
and is the cause of high morbidity and mortality [7,8]. It is believed that most infections 
occur during early childhood, e.g. during birth or early family life. [9]. If infected at birth, 
children have a 90% risk of developing chronic infection. This rate decreases to 30% if 
infected between the ages of one and five and to 5-10% if infected after the age of 5 [10]. As 
screening for hepatitis B surface antigen (HBsAg) in pregnant women and immunoglobulin 
prophylaxis in newborns are not widely practiced in Lao PDR, routine infant vaccination is 
the mainstay of the prevention of early childhood infection. 
From 2001, there has been a phased introduction of HBV vaccine into the national 
immunization schedule. Currently, infants are scheduled to receive the HBV birth dose within 
24 hours after birth, followed by HBV containing vaccine at 6, 10 and 14 weeks of age in 
combination with diphtheria, tetanus, pertussis and Haemophilus influenzae b vaccine (DTP- 
HepB-Hib) [11-13]. The birth dose of HBV vaccine, followed by the timely 3 dose schedule, 
is assumed 70 to 95% effective in preventing mother-to-child transmission of HBV [4,14-16]. 
However, the HBV birth dose coverage in Lao PDR was only approximately 28% in 2011–
2012 [13], largely because the majority of births are unattended home-births (62% in 2010 
[17]). A recent study showed that even among infants born at health-care facilities, the birth 
dose vaccination coverage was only 74%. The study also showed that missing stock and 
misconceptions around vaccine contraindications were major issues that should be addressed. 
In addition, the authors highlighted a need to strengthen HepB birth dose inclusion in home 
birthing and post-natal services and increase the percentage of medically attended home-
births and postnatal home visits [16]. Furthermore, due to the difficult access to healthcare for 
a large proportion of the Lao population, only 78% of children less than 1 year old received 
all three DTP-HepB-Hib vaccinations in 2011 [17]. 
Currently there are no serological studies in young people and pregnant women in Lao PDR. 
To better understand the epidemiology of hepatitis B and the impact of immunisation on the 
disease, we performed a cross-sectional survey in four different sub-populations from Lao 
PDR with different ages and vastly different access to vaccination and general health care; 
infants, pre-school children, school pupils and pregnant women. 
Methods 
Study population 
We recruited participants from 5 different provinces in Lao PDR; Luang Prabang in the north 
of the country, Huaphan in the northeast, Vientiane and Boulhikhamxai in the centre and 
Savannakhet in the south (Table 1). The study was approved by the Laos National Ethics 
Committee (reference NECHR 001/2011for infants, school students and pregnant women; 
reference 2013–732 for pre-school children in Huaphan province). As none of the participant 
selection was systematically randomised, we cannot exclude different selection bias in the 
different groups. 
Table 1 Participant profile 
Participants Infants (9 months; 
Luang Prabang and 
Vientiane Capital) 
Pre-school aged 
children (1–4 years; 
Huaphan) 
School children (5–19 years; 
Luang Prabang, Boulhikhamxai, 
Savannakhet) 
Pregnant women (16–46 
years; Luang Prabang and 
Vientiane Capital) 
Total 
Male 93 72 835 0 1015 
Female 104 60 909 398 1492 
Total 197 132 1744 398 2471 
N° tested 192 132 1689 388 2401 
Infants 
Infants aged 9–16 months were recruited following maternal informed consent. All 197 
enrolled infants were attending vaccination clinics in Luang Prabang Provincial hospital or 
the Vientiane Mother and Child Central Hospital on predetermined days in 2011. 
Pre-school aged children 
A total of 132 pre-school aged children (1–4 years) were recruited from rural settings in 
Huaphan province Xamtai and Kuan districts, in 2013. Mothers were informed by the village 
chief of the date and place of the upcoming study. All mothers that attended the recruitment 
site with their children and gave informed consent were enrolled. Out of 415 parents 
informed about the study, only 132 gave consent for their child’s enrollment due to the very 
complicated living conditions in this rural setting. 
Immunization status was determined from certificates of vaccination (yellow cards) when 
available. Nutritional status was estimated by weight/height ratio and medium upper left arm 
circumference (MUAC). Villages were defined as being remote from health centres when the 
travel time exceeded 100 minutes by the most rapid means of transport. 
School pupils 
School pupils (n = 1744) aged 5–19 years participating in a 2011 national immunization 
campaign against measles and rubella were recruited from semi-urban areas of the following 
provinces; Luang Prabang, Boulhikhamxai (Paksan and Pakading districts) and Savannakhet 
(Kaisone and Outhoumphone districts). 
Pregnant women 
All pregnant women that attend the antenatal units in Luang Prabang Provincial hospital or 
the Vientiane Mother and Child Central Hospital on predetermined days in 2011 were asked 
to participate. A total of 398 women aged 16–46 years provided informed written consent and 
were enrolled in the study. 
Serological testing 
After obtaining informed consent from the parents or participants, venous blood was drawn. 
Serum was isolated by centrifugation and stored at −80°C until testing. Commercially 
available enzyme immunoassay kits (Diasorin, Italy) were used for the detection of HBsAg 
(Murex HBsAg kit) and antibodies against hepatitis B surface antigen (anti-HBs; EIT-AB-
AUK3 kit) and core antigen (anti-HBc; Murex anti-HBc kit). HBsAg was tested only in 
samples that were anti-HBc positive and anti-HBs negative. Although this strategy may miss 
some subjects with early acute or low level HBV infection and immune tolerance, these 
individuals are rare and previous studies estimate that we will detect more than 99% of 
HBsAg positive individuals [7]. Positivity for HBsAg was considered indicative of chronic 
infection although a small percentage may be acute phase infections. Anti-HBs indicate a 
post-infectious or post-vaccination immunity according to the presence or absence of anti-
HBc. In the latter case, the anti-HBs alone were considered protective if greater than10 
mIU/mL. Anti-HBc alone were interpreted as a likely marker of previous exposure to the 
virus. Individuals negative for all HBV serological markers were considered seronegative. 
Data were analysed by Chi square or Fischer exact test, as appropriate, using GraphPad Prism 
and STATA software all the data were analysed anonymously. 
Results 
Seventy sera gave un-interpretable /equivocal results for anti-HBs antibodies and were 
excluded from further analysis. Of the remaining 2401 samples, 294 (12.2%) were positive 
for anti-HBc alone, 459 (19.1%) for anti-HBs alone and 296 (12.3%) for both anti-HBc and 
anti-HBs while 1352 (56.3%) were negative for all serum markers. HBsAg positive samples 
represented 7.2% of all individuals and 58.5% of anti-HBs negative, anti-HBc positive 
participants (Figure 1 and Table 2). 
Figure 1 Seroprevalence of anti-HBs and anti-HBc antibodies according to age. Numbers 
above bars represent the number of participants per age group. These data exclude those who 
had equivocal results. 
Table 2 HBV serology in infants, school pupils and pregnant women according to location 
 Infants N (%) Pre-school children N (%) School pupils N (%) Pregnant women N (%) 
VTN LPB Total Huaphan LPB BLX SVN Total VTN LPB Total 
anti-HBs- anti-HBc- 23 (24.5) 31 (31.6) 54 (28.1) 86 (65.1) 318 (53.4) 358 (63.9) 369 (69.2) 1045 (61.9) 98 (51.9) 69 (34.7) 167 (43.0) 
anti-HBs + anti-HBc - 61 (64.9) 54 (55.1) 115 (59.9) 18 (13.6) 131 (22.0) 108 (19.3) 58 (10.9) 297 (17.6) 6 (3.2) 23 (11.6) 29 (7.5) 
anti-HBs– anti-HBc + 7 (7.5) 5 (5.1) 12 (6.3) 13 (9.9) 61 (10.2) 57 (10.2) 75 (14.1) 193 (11.4) 30 (15.9) 46 (23.1) 76 (19.6) 
anti-HBs + anti-HBc+ 3 (3.2) 8 (8.2) 11 (5.7) 15 (11.4) 86 (14.4) 37 (6.6) 31 (5.8) 154 (9.1) 55 (29.1) 61 (30.7) 116 (29.9) 
HBsAg + * 1 (1.1) 0 1 (0.5) 6 (4.5) 50 (8.4) 20 (3.6) 63 (11.8) 133 (7.9) 18 (9.5) 14 (7.0) 32 (8.2) 
Total 94 98 192 132 596 560 533 1689 189 199 388 
*only tested on anti-HBs negative - anti-HBc positive samples. 
Abbreviations used: VTN Vientiane, LPB Luang Prabang, BLX Bolikhamxai and SVN Savannaket. 
Infants 
In total, 132 infant samples from Luang Prabang and Vientiane were tested. Overall anti-HBc 
prevalence was 12.0% with 6.3% positive for anti-HBc alone. Anti-HBs antibodies alone 
were detected in 59.9%. Both anti-HBc and anti-HBs were detected in 5.7% of infants. Anti-
HBs negative, unprotected infants represented 34.4% of all tested. Only 0.5% of infants were 
HBsAg positive (Figure 1 and Table 2). 
Pre-school aged children 
Anti-HBc and anti-HBs antibody prevalence in pre-school aged children from remote areas of 
Huaphan province was 21.2% and 25.0%, respectively. Thus, 75% of the pre-school children 
remained anti-HBs negative and susceptible to infection. Anti-HBc antibodies alone were 
detected in 9.9% of pre-school aged children and anti-HBs alone in 13.6% of children with 
11.4% positive for both antibodies. HBsAg was detected in 4.6% of the children (Figure 1 
and Table 2). Only 66 (50%) were able to present their certificate of vaccination (yellow 
card). Protective anti-HBs antibodies were detected in 19.7% of participants without 
vaccination records and 30.3% of those with vaccination records; 15 of the 55 children 
(27.2%) with records showing 3 doses of DTP-HepB-Hib vaccine and in one of the 14 
children (7.1%) who received a birth dose of HepB vaccine followed by 3 doses of DTP-
HepB-Hib (Table 3). Prevalence of anti-HBs alone, indicative of vaccination, was 19.5% in 
villages close to health centres as compared to 4.0% in remote villages (p = 0.01). Stunted 
and underweight children comprised 51.5% and 21.2% of those with protective levels of anti-
HBs antibodies respectively as compared to 53.5% and 27.3% of those without anti-HBs (not 
significant). The prevalence of acute malnutrition, as measured by weight/ height and MUAC 
was 3% and 6% in those with protective anti-HBs titres compared to 3% and 10.1% in those 
without anti-HBs (not significant). HBsAg was detected in 4.5% of the pre-school children. 
Table 3 Vaccination and serological status of pre-school children from Huaphan 
province 
Vaccine received as documented on yellow card Children who received 
vaccine N (%) 
Children with anti-HBs 
antibodies N (%) 
No HepB birth dose DTP-HepB-Hib 1 9 5 (55.6%) 
DTP-HepB-Hib 2 2 0 (0%) 
DTP-HepB-Hib 3 41 14 (34.5%) 
Received HepB birth dose DTP-HepB-Hib 1 0 0 
DTP-HepB-Hib 2 0 0 
DTP-HepB-Hib 3 14 1 (7.1%) 
School children 
In total, 20.5% of the school children were anti-HBc positive and 26.7% were anti-HBs 
positive. Only 9.1% were double positive for both markers; 11.4% and 17.6% were single 
positive for anti-HBc and anti-HBs, respectively. In school children aged 9 years of age and 
under, anti-HBc and anti-HBs were 11.7% and 37.2%, respectively. HBsAg prevalence in 
this age-group was 4.1%. School children aged between 10 and 14 years had anti-HBc, anti-
HBs and HBsAg prevalence of 19.4%, 24.8%, and 7.8%, respectively. Those between the 
ages of 15 and 19 years had anti-HBc, anti-HBs and HBsAg prevalence of 27.0%, 22.3%, and 
10.2%, respectively (Figure 1 and Table 2). 
HBsAg prevalence was significantly higher among those from Savannaket (11.8%) than from 
Boulhikhamxai (3.6%) or Luang Prabang (8.4%; p < 0.05). The average age of school pupils 
did not significantly differ between Savannakhet (14.6 years), Luang Prabang (11.7 years) 
and Boulhikhamxai (12.6 years). 
Pregnant women 
Anti-HBc prevalence was 49.5% in pregnant women; 19.6% were anti-HBc positive alone 
and 29.9% were double positive for anti-HBc and anti-HBs. Anti-Hbs prevalence was 37.4%; 
7.5% for anti-HBs alone without anti-HBc. HBsAg was detected in 8.2% of the pregnant 
women in this study (Figure 1 and Table 2). 
Discussion 
Among the 192 infants aged 9 to16 months tested in the urban settings of Vientiane and 
Luang Prabang, only one carried HBsAg while 23 (12%; all were aged 9–10 months) were 
anti-HBc positive. Anti-HBc positivity, usually indicative of HBV exposure, may also be 
attributed to passive transfer of maternal antibodies still detectable at this age. For instance, in 
African children aged 3 months to 6 years, the seroprevalence of anti-HBc was 44.4% during 
the first 6 months of age and still 18.8% at 12 months [7,18]. Importantly, the low HBsAg 
prevalence in the infants in our study may be seen as a positive impact of the vaccination 
policy implemented in the districts. This is also supported by the 59.9% seroprevalence rate 
of anti-HBs alone, reflecting an active, albeit low-level, immunization campaign in these 
areas. The three doses of HBV vaccine against hepatitis B were introduced in the EPI of the 
Lao PDR in 2001 and the birth dose was added in 2003 [13,17]. Consequently, all infants 
included in our study should have received 4 doses of vaccine against HBV and be anti-HBs 
positive. However, our results show that vaccination coverage among infants even in the 
main cities of Luang Prabang and Vientiane remains inadequate. This is in line with the low 
vaccination coverage with the HBV birth dose (44-48%) and the DTP-HepB-Hib3 (80-85%) 
reported from these cities in 2011 [13,17]. It can be expected that in a rural setting the 
coverage is even lower. 
Indeed only 13.6% of our pre-school children aged 1 to 4 years from rural settings in 
Huaphan province had anti-HBs antibodies alone, suggesting that very few children had been 
vaccinated. Distance from the nearest health centre was significantly associated with 
vaccination status, emphasizing the relationship between access and vaccination coverage (p 
= 0.01). In contrast 21.3% were anti-HBc positive, reflecting a prior exposure to HBV in this 
age group rather than passive transfer of maternal antibodies. Furthermore, 4.5% were 
HBsAg carriers as a result of early life exposure. That only 27% of 55 children who received 
three doses of DTP-Hib-HepB vaccine according to their yellow vaccination cards had 
protective levels of anti-HBs antibodies is of further concern. Altered immunogenicity of the 
vaccine because of deficiencies in the cold chain [9,19] or because of expired batches may be 
one explanation. In our study a high percentage of the children were stunted (low height for 
ages) and underweight (low weight for age). However, we did not find a lower vaccine 
response in malnourished children as compared to those who were not malnourished, similar 
to the findings of previous studies [20]. Unreliable certification of vaccination in the yellow 
cards by the mobile teams would be another explanation of major concern. 
The school pupils in our study were recruited from semi-urban settings in Luang Prabang, 
Boulhikhamxai and Savannakhet provinces. Those aged 9 and under were born after the 
introduction of the HBV vaccines. The HBsAg prevalence increased from 4.3% (similar to 
the 4.5% in the under-fives in Huaphan province) in the 5 to 9 years old to 7.8% between 10 
and 14 years. Assuming that most chronic infections are acquired during the first years of 
life, the lower HBsAg prevalence can be considered as the result of an improved vaccination 
coverage. The increase of anti-HBc prevalence from 19.4% in the 10 to 14 years old to 27.0% 
in the 15 to 19 years bracket shows that HBV exposure continues and may even intensify 
after the age of 14 years. The higher HBsAg prevalence in the province of Savannakhet is of 
note. This cannot be explained by age difference and is perhaps a reflection of variable 
vaccination coverage between provinces. As we had no vaccination histories for the school 
pupils, we could not address this issue further. The high HBsAg prevalence that we detect is 
in contrast to a recent nationwide study which reported low prevalence (1.7%) in children 
aged 5–9 years of age [21]. We mainly attribute these differences to a possible lower 
sensitivity of the rapid test used in the latter study or logistical differences such as sampling 
methodology. 
The pregnant women in our study were recruited from urban areas of Luang Prabang and 
Vientiane. The high HBsAg prevalence of 8.2% in this cohort represents a high risk of 
vertical transmission of HBV and stresses the need to promote HBV vaccination of all 
children at birth, a strategy that has proved effective in many other countries within the 
region [22,23]. This prevalence is in accordance with published studies [7,8] and unpublished 
data from the Lao Red Cross that show between 8–10% of adult Lao blood donors 
nationwide are HBsAg positive. However, it is in contrast to the 2.9% HBsAg positivity in 
mothers aged 15–49 years in the aforementioned nationwide survey [21]. Regional HBsAg 
prevalence varies between and within countries, according to vaccination coverage and other 
factors. Thus, studies in Vietnam, Cambodia and southern China have also reported high 
adult HBsAg prevalences of 7 to 20% [22-26]. 
Conclusions 
Strengthening the policy for preventing mother to child transmission of HBV in Lao PDR is 
needed to reach the objective of reducing the prevalence of HBsAg carriage below 1% in 
children aged less than 5 years. We gave examples from rural and semi-urban settings in 5 
different provinces that sub-optimal coverage of the HBV vaccine birth dose since its 
introduction in 2003 threatens the possibility of achieving this objective. Our study suggests 
some major short comings of the outreach programme including low vaccination coverage 
but also problems with vaccine responses and/or flawed vaccination cards. Another obstacle 
to this important public health intervention is that the majority of children are born at home 
largely without medical attention indicating that the “dose at birth” is probably given too late 
or not at all in particular in remote rural areas. We also highlight that even in areas best-
supported by the health system, exposure to HBV among unvaccinated individuals occurs 
during secondary school and continues throughout adulthood. 
Lao PDR is heterogeneous in terms of vaccination coverage and access to healthcare. For 
example infants attending health facilities in urban areas have better access to vaccination 
than children from rural settings who comprise the largest proportion in Lao PDR. Because of 
geographical and ethnic heterogenicity and non-randomised sampling it is difficult and even 
not indicated to extrapolate our seroprevalence data to the entire Lao population. 
Nevertheless, we clearly show that there is a positive impact of HBV vaccine as evidenced by 
low prevalence of HBsAg in infants and school-children under 10 years i.e. those born after 
its introduction. 
Therefore strengthening hygienic interventions or providing an additional HBV vaccine dose 
at 10 years of age should be considered. A significant improvement in immunization 
coverage of children would also require strengthening routine outreach services, by mobile 
teams, especially in remote areas, paired with a strict management of the cold chain and 
reliable certification of vaccinations. 
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